Clinical Trials Browser

Leukemia, Recurrence, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT02664935 2025-05-21

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

Phase 2 Active not recruiting

423 enrolled

Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

NCT03903835 2025-04-09

ProBio

Phase 3 Recruiting

750 enrolled

Genitourinary

Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT06607757 2025-04-02

Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer

Phase 2 Recruiting

120 enrolled

CCCA Assessed by Ki67 Drop Below <2.7% From Baseline

NCT02423603 2025-03-10

PAKT

Phase 2 Completed

71 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT02299999 2025-01-15

SAFIR02_Breast

Phase 2 Active not recruiting

1,460 enrolled

Breast

Breast Neoplasms

NCT02338622 2024-09-26

ComPAKT

Phase 1 Completed

60 enrolled

Advanced Cancer

NCT05720260 2024-06-10

Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC

Phase 2 Recruiting

42 enrolled

Breast

Breast Neoplasms

NCT02117167 2024-01-10

SAFIR02_Lung

Phase 2 Completed

999 enrolled

Thoracic

Non-small Cell Lung Cancer Metastatic

NCT03310541 2023-05-06

AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations

Phase 1 Completed

12 enrolled

BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

NCT02576444 2022-12-28

OLAPCO

Phase 2 Terminated

67 enrolled 10 charts

Tumor-Agnostic

Neoplasms

NCT02121639 2022-05-05

ProCAID

Phase 1/2 Completed

160 enrolled

Genitourinary

Prostatic Neoplasms

NCT02451956 2019-12-30

Study of AZD5363 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring PIK3CA Mutation and/or PIK3CA Amplification as a Second-line Chemotherapy

Phase 2 Completed

21 enrolled

Gastrointestinal

Advanced Gastric Cancer

NCT03182634 2019-01-22

plasmaMATCH

Phase 2 Unknown

1,150 enrolled

Breast

Advanced Breast Cancer

NCT02525068 2018-08-08

RE-AKT

Phase 2 Unknown

136 enrolled

Genitourinary

Adenocarcinoma of the Prostate

NCT02077569 2017-05-04

STAKT

Phase 2 Completed

48 enrolled

Breast

Breast Neoplasms

Clinical Trials

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Precision

CAVALRY

CAPIcorn

AMTEC IIT: Phase 2 Multiarm Study in TNBC

SAFE-CAP

ESMART

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

CaptAin

HEM-iSMART E

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

ProBio

Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer

PAKT

SAFIR02_Breast

ComPAKT

Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC

SAFIR02_Lung

AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations

OLAPCO

ProCAID

Study of AZD5363 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring PIK3CA Mutation and/or PIK3CA Amplification as a Second-line Chemotherapy

plasmaMATCH

RE-AKT

STAKT